Observing quality of life in patients after bladder cancer surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study follows patients who have undergone radical cystectomy for muscle-invasive bladder carcinoma over a period of approximately 10 years. Participants will be contacted yearly to complete questionnaires regarding their quality of life and pathological state, with data collected adhering to strict privacy and good clinical practice standards. The study aims to gather comprehensive data on the pre-surgery symptoms, hospitalization details, and long-term outcomes of these patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* subjects underwent radical cystectomy
* \> 18 years old
* Ability to read and sign the informed consent

Exclusion Criteria:

* Age \<18 years
* Inability to read and sign the informed consent

Where it's running

• IRCCS Ospedale San Raffaele
  Milan, Mi, Italy Recruiting

Study contacts

• Principal investigator: Francesco Montorsi, MD — IRCCS Ospedale San Raffaele
• Study coordinator: Francesco Montorsi, MD
• Email: montorsi.francesco@hsr.it
• Phone: +390226437286

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Bladder cancer: test a biomarker-guided plan after neoadjuvant therapy

  This phase 2 study tests a biomarker- and response-guided plan to preserve the bladder in patients with muscle-invasive bladder cancer after neoadjuvant therapy.

  Recruiting Phase 2 Fox Chase Cancer Center · Philadelphia, Pennsylvania · NCT07908979

• BL-M07D1: T-bren vs standard platinum chemo for HER2-expressing metastatic urothelial cancer after anti-PD-(L)1 therapy

  This trial tests whether T-bren can help people with HER2-expressing metastatic urothelial cancer who progressed after anti-PD-(L)1 therapy, compared with standard platinum-based chemotherapy.

  Recruiting at 2 sites Phase 3 SystImmune Inc. · Macon, Georgia and 1 other locations · NCT07869836

• New combination therapy for HER2-positive muscle-invasive bladder cancer

  A phase 2, multi-center study tests four sensitizing drugs with disitamab vedotin and toripalimab in adults with HER2-positive muscle-invasive bladder cancer to see if the treatment can lead to tumor reduction and potential bladder preservation.

  Recruiting Phase 2 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07717242

• Sexual health support after bladder cancer treatment

  This project will try sexological support to help adults about 12 months after bladder cancer treatment improve sexual function and intimacy.

  Recruiting University of Aarhus · Aarhus · NCT07339761

• Ureteral stent versus no stent for adults having radical cystectomy with an ileal conduit

  This trial tests whether placing temporary ureteral stents at the time of radical cystectomy with ileal conduit reduces post-operative complications compared with not placing stents in adults having cystectomy for bladder or other pelvic cancers.

  Recruiting Thomas Jefferson University · Philadelphia, Pennsylvania and 1 other locations · NCT07234968

• Assessing late images in PET-CT for bladder cancer staging

  This study is testing if taking later images during a PET-CT scan can help better identify lymph node involvement in patients with muscle-invasive bladder cancer.

  Recruiting Hopital Foch · Suresnes, Île-de-France Region · NCT06537960

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.